Mizuho Turns Bullish on Acadia: Upgrades ACAD to Outperform, Lifts Target to $35 on Remlifanserin Promise

Mizuho upgrades ACAD stock to Outperform with a $35 price target, highlighting undervalued potential in remlifanserin for Alzheimer’s psychosis, despite past setbacks with pimavanserin.